Digi.Bio develops a Desktop Biofoundry that utilizes digital microfluidics and electrowetting to automate liquid handling processes in biological research. This technology enables precise control over multistep workflows, significantly reducing the time and labor required for experimental setups in laboratories.
Funding
$343.2K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for analyzing cell-based therapies are often manual, time-consuming, and lack the ability to capture single-cell dynamics and heterogeneity. This makes it difficult to fully understand drug performance and cell interactions over time, hindering the development of effective therapies.
Solution
Digi.Bio offers a Desktop Biofoundry that automates and miniaturizes multistep liquid handling applications using digital microfluidics and electrowetting. This lab-on-a-chip technology enables researchers to gain fine-grained experimental control and streamline workflows for single-cell analysis. The platform facilitates real-time tracking and comparison of cytotoxicity data, allowing for identification of top-performing drugs. Digi.Bio's system measures each cell's fate and performance individually, revealing insights into therapeutic efficacy and heterogeneity within cell populations. The AI-driven analysis reconstructs cell trajectories and interactions, providing a comprehensive understanding of cell behavior in response to therapy.
Target Audience
The primary audience includes researchers and companies in the pharmaceutical, diagnostics, and industrial biotech sectors, particularly those focused on cell-based therapies and drug development.
Features
- Desktop Biofoundry automates liquid handling using digital microfluidics and electrowetting.
- Enables precise control and miniaturization of experimental protocols.
- Facilitates real-time tracking and comparison of cytotoxicity data.
- AI-based analysis reconstructs cell trajectories, cell-cell interactions, and target cell engagement.
- Measures the dynamics and therapeutic efficacy of individual cells.
- Identifies stained and label-free cell types and assesses viability.
- Tracks cell motility and analyzes cell-cell interaction kinetics.
- Automates cytotoxicity testing without the need for an operator.